BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Aureka Biotechnologies Raises $100M Series B to Advance AI-Driven Drug Discovery

Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and ...

August 12, 2026 | News

Mabwell Clears Brazil ANVISA GMP Inspection for Denosumab Biosimilars

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned...

August 11, 2026 | News

Innovent, Daiichi Sankyo Partner to Commercialise Vanflyta for FLT3-ITD Positive AML in China

Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML Innovent Bio...

August 11, 2026 | News

RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy ...

August 10, 2026 | News

Ono and Mediar Partner to Develop Novel Antibody Therapies for Fibro-Inflammatory Diseases

Commencing a drug discovery partnership to create novel antibody therapeutics for fibro-inflammatory diseases with high unmet medical need Leveraging ...

August 10, 2026 | News

Porton Advanced Secures China Commercial Manufacturing Licence for Cell and Gene Therapy CDMO Services

Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Admi...

August 07, 2026 | News

Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic

Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...

August 07, 2026 | News

Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea

Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex...

August 07, 2026 | News

Biocon Launches Interchangeable YESAFILI Biosimilar to EYLEA in the U.S.

Yesafili™ (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg Potential ...

August 06, 2026 | News

Forlong Biotechnology Completes Pivotal FL115 Manufacturing Milestone Ahead of Phase III NMIBC Trial

Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today...

August 06, 2026 | News

10 Bioprocessing Bottlenecks and How APAC Plants Are Clearing Them

How this list was built Ten bottlenecks were identified from facility interviews, technical sessions at regional bioprocessing conferences and pub...

August 05, 2026 | Analysis

Vaxcellbio Partners with Myellama to Advance Next-Generation NK Cell Therapy for Multiple Myeloma

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced today that it has signed a strategic Memorandum of Understanding ...

August 05, 2026 | News

MARS Bioimaging Secures First Clinical Sale of Portable Photon-Counting CT System

Christchurch-based Reform Radiology becomes inaugural clinical customer as New Zealand-developed photon-counting CT technology enters routine clinical&nb...

August 05, 2026 | News

GlycoNex Doses First Patient in Phase I Trial of Novel Glycan-Targeting ADC GNX1021

GlycoNex Inc. announced that the first patient has been successfully dosed in the First-in-Human (FIH) Phase I clinical trial of GNX1021, the Company's nov...

August 04, 2026 | News

Stay Connected